Our regulatory practice advises clients across the sector including pharmaceuticals and biotechnology, cell and gene therapies, veterinary medicine, medical devices, in vitro-diagnostics and digital health. Our team has a variety of backgrounds, within the fields of bioscience, genetics and neuroscience.

As most of our lawyers have spent some time in-house, we understand the priorities faced by our clients in the day-to-day running of their business and navigating the national and EU framework.

We advise leading international companies on the full range of strategic issues arising during the life cycle of a product, from its development to its commercialisation. This encompasses advising, amongst other things, on clinical trials, marketing authorisations, CE Marking, recalls, the legal implications of parallel trade and market access.

“Regulatory IP” rights are a vital issue for our clients and we help clients analyse their products in development together with the IP regulatory rights available under the regulatory legal framework (such as regulatory data protection, orphan exclusivities, SPC and paediatric rewards).

We have a deep understanding of the challenges that medical device and IVD companies face in light of the MDR (and IVDR) revolution.

Our team represents clients before the national and European courts as well as before the competent authorities, including the European Commission, the European and UK medicines authorities (EMA and MHRA), Notified Bodies, the National Institute for Health and Care Excellence (NICE), the Department of Health, NHS England, the HFEA and the HTA.

We have a particular specialisation in more challenging issues such as cell and gene therapies, synthetic biology, genomics, borderline products and the use of AI.

Our team has conducted regulatory due diligence on behalf of clients acquiring or investing in businesses across the sector. We draw upon a deep sector knowledge to identify legal and regulatory risks as well as assessing them, whilst maintaining a commercial focus to resolve these potential issues.

Key contact

Alex Denoon

Contact

Publications

Biotech Review of the Year

Read here

Experience

Our client is trialling its approved medicine in two novel indications which will significantly expand the market. We analysed the “regulatory IP” opportunities for the expanded markets, which involved considerations of regulatory data protection, biosimilars and SPCs. We worked with our competition team to finalise the advice.

For some years, we have helped our client navigate multiple regulatory hurdles to develop an innovative system to deliver medicines directly into the brain. The therapy poses multiple challenges for regulators, but promises to revolutionise conditions ranging from Parkinson’s to glioma.

Latest articles

What others say

“Bristows was a valued partner in the success of making our vision become a reality.”

Stephanie Morris, Director of Industry Partnerships and Commercialisation at Imperial College London

“They enabled a very positive conclusion to the overall deal.”

Richard Fagan, Director of BioPharma at UCL Business

“Their expertise made them the perfect partner to work with on the highly complex Apollo transaction.”

Richard Fagan, Director of BioPharma at UCL Business

“UCLB has worked with Bristows for over 25 years, in relation to intellectual property licensing transactions as well as corporate transactions such as spinout formation.”

Richard Fagan, Director of BioPharma at UCL Business

“Bristows’ knowledge of the life sciences market and players, as well as their licensing expertise, was invaluable as we navigated this complex transaction.”

Iain Thomas, Cambridge Enterprise’s Head of Life Sciences

Recent rankings and awards

Life Sciences and Healthcare - Tier 1
Legal 500 2021

Life Sciences - Band 1
Chambers and Partners UK 2021

Life Sciences: Transactional - Band 2
Chambers and Partners UK 2021

Life Sciences - Band 4
Chambers and Partners Global 2021

Life Sciences - Band 4
Chambers and Partners Europe 2021